Misplaced Pages

Latest revision as of 03:03, 25 December 2024

Anemia
Other names	Anaemia, erythrocytopenia
Blood smear showing iron-deficiency anemia, with small, pale red blood cells
Pronunciation	/əˈniːmiə/
Specialty	Hematology
Symptoms	Feeling tired, pale skin, weakness, shortness of breath, feeling faint
Causes	Blood loss, decreased red blood cell production, increased red blood cell breakdown
Diagnostic method	Blood hemoglobin measurement
Frequency	1.92 billion / 24% (2021)

Anemia or anaemia (British English) is a blood disorder in which the blood has a reduced ability to carry oxygen. This can be due to a lower than normal number of red blood cells, a reduction in the amount of hemoglobin available for oxygen transport, or abnormalities in hemoglobin that impair its function.

The name is derived from Ancient Greek ἀν- (an-) 'not' and αἷμα (haima) 'blood'. When anemia comes on slowly, the symptoms are often vague, such as tiredness, weakness, shortness of breath, headaches, and a reduced ability to exercise.

When anemia is acute, symptoms may include confusion, feeling like one is going to pass out, loss of consciousness, and increased thirst. Anemia must be significant before a person becomes noticeably pale. Additional symptoms may occur depending on the underlying cause. Anemia can be temporary or long term and can range from mild to severe.

Anemia can be caused by blood loss, decreased red blood cell production, and increased red blood cell breakdown. Causes of blood loss include bleeding due to inflammation of the stomach or intestines, bleeding from surgery, serious injury, or blood donation. Causes of decreased production include iron deficiency, folate deficiency, vitamin B₁₂ deficiency, thalassemia and a number of bone marrow tumors. Causes of increased breakdown include genetic disorders such as sickle cell anemia, infections such as malaria, and certain autoimmune diseases like autoimmune hemolytic anemia.

Anemia can also be classified based on the size of the red blood cells and amount of hemoglobin in each cell. If the cells are small, it is called microcytic anemia; if they are large, it is called macrocytic anemia; and if they are normal sized, it is called normocytic anemia. The diagnosis of anemia in men is based on a hemoglobin of less than 130 to 140 g/L (13 to 14 g/dL); in women, it is less than 120 to 130 g/L (12 to 13 g/dL). Further testing is then required to determine the cause.

Treatment depends on the specific cause. Certain groups of individuals, such as pregnant women, can benefit from the use of iron pills for prevention. Dietary supplementation, without determining the specific cause, is not recommended. The use of blood transfusions is typically based on a person's signs and symptoms. In those without symptoms, they are not recommended unless hemoglobin levels are less than 60 to 80 g/L (6 to 8 g/dL). These recommendations may also apply to some people with acute bleeding. Erythropoiesis-stimulating agents are only recommended in those with severe anemia.

Anemia is the most common blood disorder, affecting about a fifth to a third of the global population. Iron-deficiency anemia is the most common cause of anemia worldwide, and affects nearly one billion people.

In 2013, anemia due to iron deficiency resulted in about 183,000 deaths – down from 213,000 deaths in 1990. This condition is most prevalent in children with also an above average prevalence in elderly and women of reproductive age (especially during pregnancy). Anemia is one of the six WHO global nutrition targets for 2025 and for diet-related global targets endorsed by World Health Assembly in 2012 and 2013. Efforts to reach global targets contribute to reaching Sustainable Development Goals (SDGs), with anemia as one of the targets in SDG 2 for achieving zero world hunger.

Signs and symptoms

A person with anemia may not have any symptoms, depending on the underlying cause, and no symptoms may be noticed, as the anemia is initially mild, and then the symptoms become worse as the anemia worsens. A patient with anemia may report feeling tired, weak, decreased ability to concentrate, and sometimes shortness of breath on exertion. These symptoms are unspecific and none of the symptoms alone or in combination show a good predictive value for the presence of anemia in non-clinical patients.

Symptoms of anemia can come on quickly or slowly. Early on there may be few or no symptoms. If the anemia continues slowly (chronic), the body may adapt and compensate for this change. In this case, no symptoms may appear until the anemia becomes more severe. Symptoms can include feeling tired, weak, dizziness, headaches, intolerance to physical exertion, shortness of breath, difficulty concentrating, irregular or rapid heartbeat, cold hands and feet, cold intolerance, pale or yellow skin, poor appetite, easy bruising and bleeding, and muscle weakness.

Anemia that develops quickly, often, has more severe symptoms, including, feeling faint, chest pain, sweating, increased thirst, and confusion. There may be also additional symptoms depending on the underlying cause.

In more severe anemia, the body may compensate for the lack of oxygen-carrying capability of the blood by increasing cardiac output. The person may have symptoms related to this, such as palpitations, angina (if pre-existing heart disease is present), intermittent claudication of the legs, and symptoms of heart failure.

On examination, the signs exhibited may include pallor (pale skin, mucosa, conjunctiva and nail beds), but this is not a reliable sign.

Iron-deficiency anemia may give symptoms that can include spoon-shaped nails, restless legs syndrome, and pica (the medical condition indicates the desire for things that are not food, such as ice, dirt, etc.). A blue coloration of the sclera may be noticed in some cases of iron-deficiency anemia. Vitamin B₁₂ deficiency anemia may result in decreased ability to think, memory loss, confusion, personality or mood changes, depression, difficulty walking, blurred vision, and irreversible nerve damage. Other specific causes of anemia may have signs and/or complications such as, jaundice with the rapid break down of red blood cells as with hemolytic anemia, bone abnormalities with thalassemia major, or leg ulcers as seen in sickle cell disease.

In severe anemia, there may be signs of a hyperdynamic circulation: tachycardia (a fast heart rate), bounding pulse, flow murmurs, and cardiac ventricular hypertrophy (enlargement). There may be signs of heart failure. Pica, the consumption of non-food items such as ice, paper, wax, grass, hair or dirt, may be a symptom of iron deficiency; although it occurs often in those who have normal levels of hemoglobin. Chronic anemia may result in behavioral disturbances in children as a direct result of impaired neurological development in infants, and reduced academic performance in children of school age. Restless legs syndrome is more common in people with iron-deficiency anemia than in the general population.

Causes

The causes of anemia may be classified as impaired red blood cell (RBC) production, increased RBC destruction (hemolytic anemia), blood loss and fluid overload (hypervolemia). Several of these may interplay to cause anemia. The most common cause of anemia is blood loss, but this usually does not cause any lasting symptoms unless a relatively impaired RBC production develops, in turn, most commonly by iron deficiency.

Impaired production

• Disturbance of proliferation and differentiation of stem cells
  • Pure red cell aplasia
  • Aplastic anemia affects all kinds of blood cells. Fanconi anemia is a hereditary disorder or defect featuring aplastic anemia and various other abnormalities.
  • Anemia of kidney failure due to insufficient production of the hormone erythropoietin
  • Anemia of endocrine disease
• Disturbance of proliferation and maturation of erythroblasts
  • Pernicious anemia is a form of megaloblastic anemia due to vitamin B₁₂ deficiency dependent on impaired absorption of vitamin B₁₂. Lack of dietary B₁₂ causes non-pernicious megaloblastic anemia.
  • Anemia of folate deficiency, as with vitamin B₁₂, causes megaloblastic anemia
  • Anemia of prematurity, by diminished erythropoietin response to declining hematocrit levels, combined with blood loss from laboratory testing, generally occurs in premature infants at two to six weeks of age.
  • Iron-deficiency anemia, resulting in deficient heme synthesis
  • Thalassemias, causing deficient globin synthesis
  • Congenital dyserythropoietic anemias, causing ineffective erythropoiesis
  • Anemia of kidney failure (also causing stem cell dysfunction)
• Other mechanisms of impaired RBC production
  • Myelophthisic anemia or myelophthisis is a severe type of anemia resulting from the replacement of bone marrow by other materials, such as malignant tumors, fibrosis, or granulomas.
  • Myelodysplastic syndrome
  • anemia of chronic inflammation
  • Leukoerythroblastic anemia is caused by space-occupying lesions in the bone marrow that prevent normal production of blood cells.

Increased destruction

Anemias of increased red blood cell destruction are generally classified as hemolytic anemias. These types generally feature jaundice, and elevated levels of lactate dehydrogenase.

• Intrinsic (intracorpuscular) abnormalities cause premature destruction. All of these, except paroxysmal nocturnal hemoglobinuria, are hereditary genetic disorders.
  • Hereditary spherocytosis is a hereditary defect that results in defects in the RBC cell membrane, causing the erythrocytes to be sequestered and destroyed by the spleen.
  • Hereditary elliptocytosis is another defect in membrane skeleton proteins.
  • Abetalipoproteinemia, causing defects in membrane lipids
  • Enzyme deficiencies
    • Pyruvate kinase and hexokinase deficiencies, causing defect glycolysis
    • Glucose-6-phosphate dehydrogenase deficiency and glutathione synthetase deficiency, causing increased oxidative stress
  • Hemoglobinopathies
    • Sickle cell anemia
    • Hemoglobinopathies causing unstable hemoglobins
  • Paroxysmal nocturnal hemoglobinuria
• Extrinsic (extracorpuscular) abnormalities
  • Antibody-mediated
    • Warm autoimmune hemolytic anemia is caused by autoimmune attack against red blood cells, primarily by IgG. It is the most common of the autoimmune hemolytic diseases. It can be idiopathic, that is, without any known cause, drug-associated or secondary to another disease such as systemic lupus erythematosus, or a malignancy, such as chronic lymphocytic leukemia.
    • Cold agglutinin hemolytic anemia is primarily mediated by IgM. It can be idiopathic or result from an underlying condition.
    • Rh disease, one of the causes of hemolytic disease of the newborn
    • Transfusion reaction to blood transfusions
  • Mechanical trauma to red blood cells
    • Microangiopathic hemolytic anemias, including thrombotic thrombocytopenic purpura and disseminated intravascular coagulation
    • Infections, including malaria
    • Heart surgery
    • Haemodialysis
  • Parasitic
    • Trypanosoma congolense alters the surfaces of RBCs of its host and this may explain T. c. induced anemia

Blood loss

• Anemia of prematurity, from frequent blood sampling for laboratory testing, combined with insufficient RBC production
• Trauma or surgery, causing acute blood loss
• Gastrointestinal tract lesions, causing either acute bleeds (e.g. variceal lesions, peptic ulcers, hemorrhoids) or chronic blood loss (e.g. angiodysplasia)
• Gynecologic disturbances, also generally causing chronic blood loss
• From menstruation, mostly among young women or older women who have fibroids
• Many type of cancers, including colorectal cancer and cancer of the urinary bladder, may cause acute or chronic blood loss, especially at advanced stages
• Infection by intestinal nematodes feeding on blood, such as hookworms and the whipworm Trichuris trichiura
• Iatrogenic anemia, blood loss from repeated blood draws and medical procedures.

The roots of the words anemia and ischemia both refer to the basic idea of "lack of blood", but anemia and ischemia are not the same thing in modern medical terminology. The word anemia used alone implies widespread effects from blood that either is too scarce (e.g., blood loss) or is dysfunctional in its oxygen-supplying ability (due to whatever type of hemoglobin or erythrocyte problem). In contrast, the word ischemia refers solely to the lack of blood (poor perfusion). Thus ischemia in a body part can cause localized anemic effects within those tissues.

Fluid overload

Fluid overload (hypervolemia) causes decreased hemoglobin concentration and apparent anemia:

• General causes of hypervolemia include excessive sodium or fluid intake, sodium or water retention and fluid shift into the intravascular space.
• From the 6th week of pregnancy, hormonal changes cause an increase in the mother's blood volume due to an increase in plasma.

Intestinal inflammation

Certain gastrointestinal disorders can cause anemia. The mechanisms involved are multifactorial and not limited to malabsorption but mainly related to chronic intestinal inflammation, which causes dysregulation of hepcidin that leads to decreased access of iron to the circulation.

• Helicobacter pylori infection.
• Gluten-related disorders: untreated celiac disease and non-celiac gluten sensitivity. Anemia can be the only manifestation of celiac disease, in absence of gastrointestinal or any other symptoms.
• Inflammatory bowel disease.

Diagnosis

Definitions

There are a number of definitions of anemia; reviews provide comparison and contrast of them. A strict but broad definition is an absolute decrease in red blood cell mass, however, a broader definition is a lowered ability of the blood to carry oxygen. An operational definition is a decrease in whole-blood hemoglobin concentration of more than 2 standard deviations below the mean of an age- and sex-matched reference range.

It is difficult to directly measure RBC mass, so the hematocrit (amount of RBCs) or the hemoglobin (Hb) in the blood are often used instead to indirectly estimate the value. Hematocrit; however, is concentration dependent and is therefore not completely accurate. For example, during pregnancy a woman's RBC mass is normal but because of an increase in blood volume the hemoglobin and hematocrit are diluted and thus decreased. Another example would be bleeding where the RBC mass would decrease but the concentrations of hemoglobin and hematocrit initially remains normal until fluids shift from other areas of the body to the intravascular space.

The anemia is also classified by severity into mild (110 g/L to normal), moderate (80 g/L to 110 g/L), and severe anemia (less than 80 g/L) in adults. Different values are used in pregnancy and children.

Testing

Anemia is typically diagnosed on a complete blood count. Apart from reporting the number of red blood cells and the hemoglobin level, the automatic counters also measure the size of the red blood cells by flow cytometry, which is an important tool in distinguishing between the causes of anemia. Examination of a stained blood smear using a microscope can also be helpful, and it is sometimes a necessity in regions of the world where automated analysis is less accessible.

A blood test will provide counts of white blood cells, red blood cells and platelets. If anemia appears, further tests may determine what type it is, and whether it has a serious cause. although of that, it is possible to refer to the genetic history and physical diagnosis. These tests may also include serum ferritin, iron studies, vitamin B₁₂, genetic testing, and a bone marrow sample, if needed.

Reticulocyte counts, and the "kinetic" approach to anemia, have become more common than in the past in the large medical centers of the United States and some other wealthy nations, in part because some automatic counters now have the capacity to include reticulocyte counts. A reticulocyte count is a quantitative measure of the bone marrow's production of new red blood cells. The reticulocyte production index is a calculation of the ratio between the level of anemia and the extent to which the reticulocyte count has risen in response. If the degree of anemia is significant, even a "normal" reticulocyte count actually may reflect an inadequate response.

If an automated count is not available, a reticulocyte count can be done manually following special staining of the blood film. In manual examination, activity of the bone marrow can also be gauged qualitatively by subtle changes in the numbers and the morphology of young RBCs by examination under a microscope. Newly formed RBCs are usually slightly larger than older RBCs and show polychromasia. Even where the source of blood loss is obvious, evaluation of erythropoiesis can help assess whether the bone marrow will be able to compensate for the loss and at what rate.

When the cause is not obvious, clinicians use other tests, such as: ESR, serum iron, transferrin, RBC folate level, hemoglobin electrophoresis, renal function tests (e.g. serum creatinine) although the tests will depend on the clinical hypothesis that is being investigated.

When the diagnosis remains difficult, a bone marrow examination allows direct examination of the precursors to red cells, although is rarely used as is painful, invasive and is hence reserved for cases where severe pathology needs to be determined or excluded.

Red blood cell size

In the morphological approach, anemia is classified by the size of red blood cells; this is either done automatically or on microscopic examination of a peripheral blood smear. The size is reflected in the mean corpuscular volume (MCV). If the cells are smaller than normal (under 80 fl), the anemia is said to be microcytic; if they are normal size (80–100 fl), normocytic; and if they are larger than normal (over 100 fl), the anemia is classified as macrocytic. This scheme quickly exposes some of the most common causes of anemia; for instance, a microcytic anemia is often the result of iron deficiency.

In clinical workup, the MCV will be one of the first pieces of information available, so even among clinicians who consider the "kinetic" approach more useful philosophically, morphology will remain an important element of classification and diagnosis. Limitations of MCV include cases where the underlying cause is due to a combination of factors – such as iron deficiency (a cause of microcytosis) and vitamin B12 deficiency (a cause of macrocytosis) where the net result can be normocytic cells.

Production vs. destruction or loss

The "kinetic" approach to anemia yields arguably the most clinically relevant classification of anemia. This classification depends on evaluation of several hematological parameters, particularly the blood reticulocyte (precursor of mature RBCs) count. This then yields the classification of defects by decreased RBC production versus increased RBC destruction or loss. Clinical signs of loss or destruction include abnormal peripheral blood smear with signs of hemolysis; elevated LDH suggesting cell destruction; or clinical signs of bleeding, such as guaiac-positive stool, radiographic findings, or frank bleeding. The following is a simplified schematic of this approach:

* For instance, sickle cell anemia with superimposed iron deficiency; chronic gastric bleeding with B₁₂ and folate deficiency; and other instances of anemia with more than one cause.
** Confirm by repeating reticulocyte count: ongoing combination of low reticulocyte production index, normal MCV and hemolysis or loss may be seen in bone marrow failure or anemia of chronic disease, with superimposed or related hemolysis or blood loss. Here is a schematic representation of how to consider anemia with MCV as the starting point:

Other characteristics visible on the peripheral smear may provide valuable clues about a more specific diagnosis; for example, abnormal white blood cells may point to a cause in the bone marrow.

Microcytic

Microcytic anemia is primarily a result of hemoglobin synthesis failure/insufficiency, which could be caused by several etiologies:

• Heme synthesis defect
  • Iron-deficiency anemia (microcytosis is not always present)
  • Anemia of chronic disease (more commonly presenting as normocytic anemia)
• Globin synthesis defect
  • Alpha-, and beta-thalassemia
  • HbE syndrome
  • HbC syndrome
  • Various other unstable hemoglobin diseases
• Sideroblastic defect
  • Hereditary sideroblastic anemia
  • Acquired sideroblastic anemia, including lead toxicity
  • Reversible sideroblastic anemia

Iron-deficiency anemia is the most common type of anemia overall and it has many causes. RBCs often appear hypochromic (paler than usual) and microcytic (smaller than usual) when viewed with a microscope.

• Iron-deficiency anemia is due to insufficient dietary intake or absorption of iron to meet the body's needs. Infants, toddlers, and pregnant women have higher than average needs. Increased iron intake is also needed to offset blood losses due to digestive tract issues, frequent blood donations, or heavy menstrual periods. Iron is an essential part of hemoglobin, and low iron levels result in decreased incorporation of hemoglobin into red blood cells. In the United States, 12% of all women of childbearing age have iron deficiency, compared with only 2% of adult men. The incidence is as high as 20% among African American and Mexican American women. In India it is even more than 50%. Studies have linked iron deficiency without anemia to poor school performance and lower IQ in teenage girls, although this may be due to socioeconomic factors. Iron deficiency is the most prevalent deficiency state on a worldwide basis. It is sometimes the cause of abnormal fissuring of the angular (corner) sections of the lips (angular stomatitis).
• In the United States, the most common cause of iron deficiency is bleeding or blood loss, usually from the gastrointestinal tract. Fecal occult blood testing, upper endoscopy and lower endoscopy should be performed to identify bleeding lesions. In older men and women, the chances are higher that bleeding from the gastrointestinal tract could be due to colon polyps or colorectal cancer.
• Worldwide, the most common cause of iron-deficiency anemia is parasitic infestation (hookworms, amebiasis, schistosomiasis and whipworms).

The Mentzer index (mean cell volume divided by the RBC count) predicts whether microcytic anemia may be due to iron deficiency or thalassemia, although it requires confirmation.

Macrocytic

• Megaloblastic anemia, the most common cause of macrocytic anemia, is due to a deficiency of either vitamin B₁₂, folic acid, or both. Deficiency in folate or vitamin B₁₂ can be due either to inadequate intake or insufficient absorption. Folate deficiency normally does not produce neurological symptoms, while B₁₂ deficiency does.
  • Pernicious anemia is caused by a lack of intrinsic factor, which is required to absorb vitamin B₁₂ from food. A lack of intrinsic factor may arise from an autoimmune condition targeting the parietal cells (atrophic gastritis) that produce intrinsic factor or against intrinsic factor itself. These lead to poor absorption of vitamin B₁₂.
  • Macrocytic anemia can also be caused by the removal of the functional portion of the stomach, such as during gastric bypass surgery, leading to reduced vitamin B₁₂/folate absorption. Therefore, one must always be aware of anemia following this procedure.
• Hypothyroidism
• Alcoholism commonly causes a macrocytosis, although not specifically anemia. Other types of liver disease can also cause macrocytosis.
• Drugs such as methotrexate, zidovudine, and other substances may inhibit DNA replication such as heavy metals

Macrocytic anemia can be further divided into "megaloblastic anemia" or "nonmegaloblastic macrocytic anemia". The cause of megaloblastic anemia is primarily a failure of DNA synthesis with preserved RNA synthesis, which results in restricted cell division of the progenitor cells. The megaloblastic anemias often present with neutrophil hypersegmentation (six to 10 lobes). The nonmegaloblastic macrocytic anemias have different etiologies (i.e. unimpaired DNA globin synthesis,) which occur, for example, in alcoholism. In addition to the nonspecific symptoms of anemia, specific features of vitamin B₁₂ deficiency include peripheral neuropathy and subacute combined degeneration of the cord with resulting balance difficulties from posterior column spinal cord pathology. Other features may include a smooth, red tongue and glossitis. The treatment for vitamin B₁₂-deficient anemia was first devised by William Murphy, who bled dogs to make them anemic, and then fed them various substances to see what (if anything) would make them healthy again. He discovered that ingesting large amounts of liver seemed to cure the disease. George Minot and George Whipple then set about to isolate the curative substance chemically and ultimately were able to isolate the vitamin B₁₂ from the liver. All three shared the 1934 Nobel Prize in Medicine.

Normocytic

Normocytic anemia occurs when the overall hemoglobin levels are decreased, but the red blood cell size (mean corpuscular volume) remains normal. Causes include:

• Acute blood loss
• Anemia of chronic disease
• Aplastic anemia (bone marrow failure)
• Hemolytic anemia

Dimorphic

A dimorphic appearance on a peripheral blood smear occurs when there are two simultaneous populations of red blood cells, typically of different size and hemoglobin content (this last feature affecting the color of the red blood cell on a stained peripheral blood smear). For example, a person recently transfused for iron deficiency would have small, pale, iron deficient red blood cells (RBCs) and the donor RBCs of normal size and color. Similarly, a person transfused for severe folate or vitamin B12 deficiency would have two cell populations, but, in this case, the patient's RBCs would be larger and paler than the donor's RBCs.

A person with sideroblastic anemia (a defect in heme synthesis, commonly caused by alcoholism, but also drugs/toxins, nutritional deficiencies, a few acquired and rare congenital diseases) can have a dimorphic smear from the sideroblastic anemia alone. Evidence for multiple causes appears with an elevated RBC distribution width (RDW), indicating a wider-than-normal range of red cell sizes, also seen in common nutritional anemia.

Heinz body anemia

Heinz bodies form in the cytoplasm of RBCs and appear as small dark dots under the microscope. In animals, Heinz body anemia has many causes. It may be drug-induced, for example in cats and dogs by acetaminophen (paracetamol), or may be caused by eating various plants or other substances:

• In cats and dogs after eating either raw or cooked plants from the genus Allium, for example, onions or garlic.
• In dogs after ingestion of zinc, for example, after eating U.S. pennies minted after 1982.
• In horses which eat dry or wilted red maple leaves.

Hyperanemia

Hyperanemia is a severe form of anemia, in which the hematocrit is below 10%.

Refractory anemia

Refractory anemia, an anemia which does not respond to treatment, is often seen secondary to myelodysplastic syndromes. Iron-deficiency anemia may also be refractory as a manifestation of gastrointestinal problems which disrupt iron absorption or cause occult bleeding.

Transfusion dependent

Transfusion dependent anemia is a form of anemia where ongoing blood transfusion are required. Most people with myelodysplastic syndrome develop this state at some point in time. Beta thalassemia may also result in transfusion dependence. Concerns from repeated blood transfusions include iron overload. This iron overload may require chelation therapy.

Treatment

The global market for anemia treatments is estimated at more than USD 23 billion per year and is fast growing because of the rising prevalence and awareness of anemia. The types of anemia treated with drugs are iron-deficiency anemia, thalassemia, aplastic anemia, hemolytic anemia, sickle cell anemia, and pernicious anemia, the most important of them being deficiency and sickle cell anemia with together 60% of market share because of highest prevalence as well as higher treatment costs compared with other types. Treatment for anemia depends on cause and severity. Vitamin supplements given orally (folic acid or vitamin B₁₂) or intramuscularly (vitamin B₁₂) will replace specific deficiencies.

Apart from that, iron supplements, antibiotics, immunosuppressant, bone marrow stimulants, corticosteroids, gene therapy and iron chelating agents are forms of anemia treatment drugs, with immunosuppressants and corticosteroids accounting for 58% of the market share. A paradigm shift towards gene therapy and monoclonal antibody therapies is observed.

Oral iron

Nutritional iron deficiency is common in developing nations. An estimated two-thirds of children and of women of childbearing age in most developing nations are estimated to have iron deficiency without anemia with one-third of them having an iron deficiency with anemia. Iron deficiency due to inadequate dietary iron intake is rare in men and postmenopausal women. The diagnosis of iron deficiency mandates a search for potential sources of blood loss, such as gastrointestinal bleeding from ulcers or colon cancer.

Mild to moderate iron-deficiency anemia is treated by oral iron supplementation with ferrous sulfate, ferrous fumarate, or ferrous gluconate. Daily iron supplements have been shown to be effective in reducing anemia in women of childbearing age. When taking iron supplements, stomach upset or darkening of the feces are commonly experienced. The stomach upset can be alleviated by taking the iron with food; however, this decreases the amount of iron absorbed. Vitamin C aids in the body's ability to absorb iron, so taking oral iron supplements with orange juice is of benefit.

In the anemia of chronic kidney disease, recombinant erythropoietin or epoetin alfa is recommended to stimulate RBC production, and if iron deficiency and inflammation are also present, concurrent parenteral iron is also recommended.

Injectable iron

In cases where oral iron has either proven ineffective, would be too slow (for example, pre-operatively), or where absorption is impeded (for example in cases of inflammation), parenteral iron preparations can be used. Parenteral iron can improve iron stores rapidly and is also effective for treating people with postpartum haemorrhage, inflammatory bowel disease, and chronic heart failure. The body can absorb up to 6 mg iron daily from the gastrointestinal tract. In many cases, the patient has a deficit of over 1,000 mg of iron which would require several months to replace. This can be given concurrently with erythropoietin to ensure sufficient iron for increased rates of erythropoiesis.

Blood transfusions

Blood transfusions in those without symptoms is not recommended until the hemoglobin is below 60 to 80 g/L (6 to 8 g/dL). In those with coronary artery disease who are not actively bleeding transfusions are only recommended when the hemoglobin is below 70 to 80g/L (7 to 8 g/dL). Transfusing earlier does not improve survival. Transfusions otherwise should only be undertaken in cases of cardiovascular instability.

A 2012 review concluded that when considering blood transfusions for anaemia in people with advanced cancer who have fatigue and breathlessness (not related to cancer treatment or haemorrhage), consideration should be given to whether there are alternative strategies can be tried before a blood transfusion.

Vitamin B₁₂ intramuscular injections

In many cases, vitamin B₁₂ is used by intramuscular injection in severe cases or cases of malabsorption of dietary-B₁₂. Pernicious anemia caused by loss of intrinsic factor cannot be prevented. If there are other, reversible causes of low vitamin B₁₂ levels, the cause must be treated.

Vitamin B₁₂ deficiency anemia is usually easily treated by providing the necessary level of vitamin B₁₂ supplementation. The injections are quick-acting, and symptoms usually go away within one to two weeks. As the condition improves, doses are reduced to weeks and then can be given monthly. Intramuscular therapy leads to more rapid improvement and should be considered in patients with severe deficiency or severe neurologic symptoms. Treatment should begin rapidly for severe neurological symptoms, as some changes can become permanent. In some individuals lifelong treatment may be needed.

Erythropoiesis-stimulating agents

The objective for the administration of an erythropoiesis-stimulating agent (ESA) is to maintain hemoglobin at the lowest level that both minimizes transfusions and meets the individual person's needs. They should not be used for mild or moderate anemia. They are not recommended in people with chronic kidney disease unless hemoglobin levels are less than 10 g/dL or they have symptoms of anemia. Their use should be along with parenteral iron. The 2020 Cochrane Anaesthesia Review Group review of erythropoietin (EPO) plus iron versus control treatment including placebo or iron for preoperative anaemic adults undergoing non-cardiac surgery demonstrated that patients were much less likely to require red cell transfusion and in those transfused, the volumes were unchanged (mean difference -0.09, 95% CI -0.23 to 0.05). Pre-operative hemoglobin concentration was increased in those receiving 'high dose' EPO, but not 'low dose'.

Hyperbaric oxygen

Treatment of exceptional blood loss (anemia) is recognized as an indication for hyperbaric oxygen (HBO) by the Undersea and Hyperbaric Medical Society. The use of HBO is indicated when oxygen delivery to tissue is not sufficient in patients who cannot be given blood transfusions for medical or religious reasons. HBO may be used for medical reasons when threat of blood product incompatibility or concern for transmissible disease are factors. The beliefs of some religions (ex: Jehovah's Witnesses) may require they use the HBO method. A 2005 review of the use of HBO in severe anemia found all publications reported positive results.

Preoperative anemia

An estimated 30% of adults who require non-cardiac surgery have anemia. In order to determine an appropriate preoperative treatment, it is suggested that the cause of anemia be first determined. There is moderate level medical evidence that supports a combination of iron supplementation and erythropoietin treatment to help reduce the requirement for red blood cell transfusions after surgery in those who have preoperative anemia.

Epidemiology

Anemia affects 27% of the world's population with iron-deficiency anemia accounting for more than 60% of it. A moderate degree of iron-deficiency anemia affected approximately 610 million people worldwide or 8.8% of the population. It is somewhat more common in females (9.9%) than males (7.8%). Mild iron-deficiency anemia affects another 375 million. Severe anaemia is prevalent globally, and especially in sub-Saharan Africa where it is associated with infections including malaria and invasive bacterial infections.

History

This section needs expansion. You can help by adding to it. (August 2020)

Signs of severe anemia in human bones from 4000 years ago have been uncovered in Thailand.

References

1. ^ Janz TG, Johnson RL, Rubenstein SD (November 2013). "Anemia in the emergency department: evaluation and treatment". Emergency Medicine Practice. 15 (11): 1–15, quiz 15–16. PMID 24716235.
2. Gardner WM, et al. (2023). "Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990–2021: findings from the Global Burden of Disease Study 2021". The Lancet Haematology. 10 (9): e713–e734. doi:10.1016/s2352-3026(23)00160-6. hdl:2164/22615. ISSN 2352-3026. PMID 37536353.
3. "Anemia: Practice Essentials, Pathophysiology, Etiology". November 9, 2021. Retrieved February 8, 2022.
4. ^ "Anemia | NHLBI, NIH". www.nhlbi.nih.gov. Retrieved February 8, 2022.
5. "anaemia". Dictionary.com. Archived from the original on July 14, 2014. Retrieved July 7, 2014.
6. "Anemia - Symptoms and causes". Mayo Clinic. Retrieved April 1, 2022.
7. Smith RE (March 2010). "The clinical and economic burden of anemia". The American Journal of Managed Care. 16 Suppl Issues: S59–66. PMID 20297873.
8. Rhodes CE, Denault D, Varacallo M (2024). "Physiology, Oxygen Transport". StatPearls. StatPearls Publishing. PMID 30855920.
9. Bhutta ZA, Das JK, Rizvi A, Gaffey MF, Walker N, Horton S, Webb P, Lartey A, Black RE (August 2013). "Evidence-based interventions for improvement of maternal and child nutrition: what can be done and at what cost?". Lancet. 382 (9890): 452–477. doi:10.1016/S0140-6736(13)60996-4. PMID 23746776. S2CID 11748341.
10. ^ Qaseem A, Humphrey LL, Fitterman N, Starkey M, Shekelle P (December 2013). "Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians". Annals of Internal Medicine. 159 (11): 770–779. doi:10.7326/0003-4819-159-11-201312030-00009. PMID 24297193. S2CID 4712203.
11. Vos T, et al. (October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282.
12. Peyrin-Biroulet L, Williet N, Cacoub P (December 1, 2015). "Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review". The American Journal of Clinical Nutrition. 102 (6): 1585–1594. doi:10.3945/ajcn.114.103366. PMID 26561626.
13. ^ "Anemia Treatment Drugs: 2019 Global Market Study; Analyzed by Type of Anemia, Type of Drug, and Geography". GlobeNewswire (Press release). April 26, 2019. Retrieved August 2, 2023.
14. ^ Vos T, et al. (December 2012). "Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet. 380 (9859): 2163–2196. doi:10.1016/S0140-6736(12)61729-2. PMC 6350784. PMID 23245607.
15. GBD 2013 Mortality Causes of Death Collaborators (January 2015). "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013". Lancet. 385 (9963): 117–71. doi:10.1016/S0140-6736(14)61682-2. PMC 4340604. PMID 25530442.
16. "WHO Global Anaemia estimates, 2021 Edition". World Health Organization. Retrieved February 27, 2022.
17. Islam MA (December 6, 2021). "Modeling the impact of campaign program on the prevalence of anemia in children under five: Anemia model". Journal of Mathematical Analysis and Modeling. 2 (3): 29–40. doi:10.48185/jmam.v2i3.362. ISSN 2709-5924.
18. "WHO | Interventions by global target". www.who.int. World Health Organization. Archived from the original on August 14, 2016.
19. "The case for action on anemia". Devex. June 14, 2016.
20. ^ eMedicineHealth > anemia article Archived 2009-04-17 at the Wayback Machine Author: Saimak T. Nabili, MD, MPH. Editor: Melissa Conrad Stöppler, MD. Last Editorial Review: 12/9/2008. Retrieved on 4 April 2009
21. "Exercising With Anemia: Prescription for Health". Medscape. Retrieved January 8, 2022.
22. Weckmann G, Kiel S, Chenot JF, Angelow A (January 24, 2023). "Association of Anemia with Clinical Symptoms Commonly Attributed to Anemia - Analysis of Two Population-Based Cohorts". Journal of Clinical Medicine. 12 (3): 921. doi:10.3390/jcm12030921. PMC 9918126. PMID 36769569.
23. ^ "What Are Symptoms of Anemia?". National Heart, Lung, and Blood Institute. March 24, 2022. Retrieved June 26, 2022.
24. "Anemia". www.hematology.org. Retrieved January 8, 2022.
25. Stevens GA, Finucane MM, De-Regil LM, Paciorek CJ, Flaxman SR, Branca F, Peña-Rosas JP, Bhutta ZA, Ezzati M (July 2013). "Global, regional, and national trends in haemoglobin concentration and prevalence of total and severe anaemia in children and pregnant and non-pregnant women for 1995–2011: a systematic analysis of population-representative data". The Lancet Global Health. 1 (1): e16–e25. doi:10.1016/s2214-109x(13)70001-9. PMC 4547326. PMID 25103581.
26. Balarajan Y, Ramakrishnan U, Özaltin E, Shankar AH, Subramanian S (December 2011). "Anaemia in low-income and middle-income countries". The Lancet. 378 (9809): 2123–2135. doi:10.1016/s0140-6736(10)62304-5. PMID 21813172.
27. Haas JD, Brownlie T (February 1, 2001). "Iron Deficiency and Reduced Work Capacity: A Critical Review of the Research to Determine a Causal Relationship". The Journal of Nutrition. 131 (2): 676S–690S. doi:10.1093/jn/131.2.676s. PMID 11160598.
28. De Franceschi L, Iolascon A, Taher A, Cappellini MD (July 2017). "Clinical management of iron deficiency anemia in adults: Systemic review on advances in diagnosis and treatment". European Journal of Internal Medicine. 42: 16–23. doi:10.1016/j.ejim.2017.04.018. PMID 28528999.
29. ^ "Mental Health and Pica". WebMD. Retrieved April 26, 2022.
30. Weksler B (2017). Wintrobe's Atlas of Clinical Hematology. Lippincott Williams & Wilkins. p. PT105. ISBN 9781451154542.
31. Hector M, Burton JR (December 1988). "What are the psychiatric manifestations of vitamin B12 deficiency?". Journal of the American Geriatrics Society. 36 (12): 1105–1112. doi:10.1111/j.1532-5415.1988.tb04397.x. ISSN 0002-8614. PMID 3057051.
32. ^ "Pernicious Anemia Clinical Presentation: History, Physical Examination". September 14, 2017. Archived from the original on September 14, 2017. Retrieved August 4, 2022.
33. Allen RP, Auerbach S, Bahrain H, Auerbach M, Earley CJ (April 2013). "The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia". American Journal of Hematology. 88 (4): 261–264. doi:10.1002/ajh.23397. PMID 23494945. S2CID 35587006.
34. "Sickle Cell Disease". National Heart, Lung, and Blood Institute. July 22, 2022.
35. ^ Table 12-1 in: Mitchell RS, Kumar V, Abbas AK, Fausto N (2007). Robbins Basic Pathology (8th ed.). Philadelphia: Saunders. ISBN 978-1-4160-2973-1.
36. Gregg XT, Prchal JT (2007). "Anemia of Endocrine Disorders". Williams Hermatology. McGraw-Hill.
37. "the definition of leukoerythroblastosis". www.dictionary.com. Archived from the original on December 2, 2018. Retrieved December 2, 2018.
38. Despotovic J, Mahoney D, Armsby C (2021). "Overview of hemolytic anemias in children". The Lecturio Medical Concept Library. UpToDate. Retrieved June 28, 2021.
39. Capriotti, Theresa (2016). Pathophysiology : introductory concepts and clinical perspectives. Frizzell, Joan Parker. Philadelphia. ISBN 978-0-8036-1571-7. OCLC 900626405.{{cite book}}: CS1 maint: location missing publisher (link)
40. Mitchell RS, Kumar V, Abbas AK, Fausto N (2007). Robbins Basic Pathology (8th ed.). Philadelphia: Saunders. p. 432. ISBN 978-1-4160-2973-1.
41. Cotran RS, Kumar V, Fausto N, Robbins SL, Abbas AK (2005). Robbins and Cotran pathologic basis of disease. St. Louis, Mo: Elsevier Saunders. p. 637. ISBN 978-0-7216-0187-8.
42. "Autoimmune Hemolytic Anemia (AIHA)" By J.L. Jenkins. The Regional Cancer Center. 2001 Archived October 7, 2009, at the Wayback Machine
43. Berentsen S, Beiske K, Tjønnfjord GE (October 2007). "Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy". Hematology. 12 (5): 361–370. doi:10.1080/10245330701445392. PMC 2409172. PMID 17891600.
44. Stijlemans B, Guilliams M, Raes G, Beschin A, Magez S, De Baetselier P (August 2007). "African trypanosomosis: From immune escape and immunopathology to immune intervention". Veterinary Parasitology. 148 (1): 3–13. doi:10.1016/j.vetpar.2007.05.005. PMID 17560035.
45. "Do Hemorrhoids Cause Iron Deficiency Anemia?". June 26, 2018.
46. Brooker S, Hotez PJ, Bundy DA (September 2008). "Hookworm-related anaemia among pregnant women: a systematic review". PLOS Neglected Tropical Diseases. 2 (9): e291. doi:10.1371/journal.pntd.0000291. PMC 2553481. PMID 18820740.
47. Gyorkos TW, Gilbert NL, Larocque R, Casapía M (April 2011). "Trichuris and hookworm infections associated with anaemia during pregnancy". Tropical Medicine & International Health. 16 (4): 531–537. doi:10.1111/j.1365-3156.2011.02727.x. PMID 21281406. S2CID 205391965.
48. Whitehead NS, Williams LO, Meleth S, Kennedy SM, Ubaka-Blackmoore N, Geaghan SM, Nichols JH, Carroll P, McEvoy MT, Gayken J, Ernst DJ, Litwin C, Epner P, Taylor J, Graber ML (December 2019). "Interventions to prevent iatrogenic anemia: a Laboratory Medicine Best Practices systematic review". Critical Care. 23 (1): 278. doi:10.1186/s13054-019-2511-9. PMC 6688222. PMID 31399052.
49. Martin ND, Scantling D (September 2015). "Hospital-Acquired Anemia: A Contemporary Review of Etiologies and Prevention Strategies". Journal of Infusion Nursing. 38 (5): 330–338. doi:10.1097/NAN.0000000000000121. PMID 26339939. S2CID 30859103.
50. Bellotto F, Cati A (March 2006). "Anemia ed ischemia miocardica: relazioni ed interferenze" [Anemia and myocardial ischemia: relationships and interferences]. Recenti Progressi in Medicina (in Italian). 97 (3): 153–164. doi:10.1701/121.1312. PMID 16700423.
51. Hung SC, Kuo KL, Peng CH, Wu CH, Wang YC, Tarng DC (2015). "Association of Fluid Retention With Anemia and Clinical Outcomes Among Patients With Chronic Kidney Disease". Journal of the American Heart Association. 4 (1): e001480. doi:10.1161/JAHA.114.001480. PMC 4330071. PMID 25559015.
52. "Fluid imbalances". Portable Fluids and Electrolytes (Portable Series). Hagerstwon, MD: Lippincott Williams & Wilkins. 2007. p. 62. ISBN 978-1-58255-678-9.
53. "ISBT: 8. Obstetric anaemia". www.isbtweb.org. Retrieved May 22, 2018.
54. Verma S, Cherayil BJ (February 2017). "Iron and inflammation - the gut reaction". Metallomics (Review). 9 (2): 101–111. doi:10.1039/c6mt00282j. PMC 5321802. PMID 28067386.
55. Guagnozzi D, Lucendo AJ (April 2014). "Anemia in inflammatory bowel disease: a neglected issue with relevant effects". World Journal of Gastroenterology (Review). 20 (13): 3542–3551. doi:10.3748/wjg.v20.i13.3542. PMC 3974521. PMID 24707137.
56. ^ Leffler DA, Green PH, Fasano A (October 2015). "Extraintestinal manifestations of coeliac disease". Nature Reviews Gastroenterology & Hepatology. 12 (10): 561–571. doi:10.1038/nrgastro.2015.131. PMID 26260366. S2CID 15561525.
57. ^ Stein J, Connor S, Virgin G, Ong DE, Pereyra L (September 2016). "Anemia and iron deficiency in gastrointestinal and liver conditions". World Journal of Gastroenterology (Review). 22 (35): 7908–7925. doi:10.3748/wjg.v22.i35.7908. PMC 5028806. PMID 27672287.
58. Catassi C, Bai JC, Bonaz B, Bouma G, Calabrò A, Carroccio A, Castillejo G, Ciacci C, Cristofori F, Dolinsek J, Francavilla R, Elli L, Green P, Holtmeier W, Koehler P, Koletzko S, Meinhold C, Sanders D, Schumann M, Schuppan D, Ullrich R, Vécsei A, Volta U, Zevallos V, Sapone A, Fasano A (September 2013). "Non-Celiac Gluten sensitivity: the new frontier of gluten related disorders". Nutrients (Review). 5 (10): 3839–3853. doi:10.3390/nu5103839. PMC 3820047. PMID 24077239.
59. James SP (April 2005). "National Institutes of Health Consensus Development Conference statement on Celiac Disease, June 28–30, 2004". Gastroenterology. 128 (4): S1–S9. doi:10.1053/j.gastro.2005.02.007. PMID 15825115.
60. Lomer MC (August 2011). "Dietary and nutritional considerations for inflammatory bowel disease". The Proceedings of the Nutrition Society (Review). 70 (3): 329–335. doi:10.1017/S0029665111000097. PMID 21450124.
61. Gerasimidis K, McGrogan P, Edwards CA (August 2011). "The aetiology and impact of malnutrition in paediatric inflammatory bowel disease". Journal of Human Nutrition and Dietetics (Review). 24 (4): 313–326. doi:10.1111/j.1365-277X.2011.01171.x. PMID 21564345.
62. Beutler E, Waalen J (March 2006). "The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration?". Blood. 107 (5): 1747–1750. doi:10.1182/blood-2005-07-3046. PMC 1895695. PMID 16189263.
63. Anemia at eMedicine
64. Rodak BF (2007). Hematology: Clinical Principles and Applications (3rd ed.). Philadelphia: Saunders. p. 220. ISBN 978-1-4160-3006-5. Archived from the original on April 25, 2016.
65. Pomeranz AJ, Sabnis S, Busey S, Kliegman RM (2016). Pediatric Decision-Making Strategies (2nd ed.). Elsevier. ISBN 978-0-323-29854-4.
66. Polin RA, Abman SH, Rowitch D, Benitz WE (2016). Fetal and Neonatal Physiology (5 ed.). Elsevier Health Sciences. p. 1085. ISBN 978-0-323-35232-1. Archived from the original on October 31, 2016.
67. Uthman E (2009). Understanding Anemia. Univ. Press of Mississippi. p. 23. ISBN 978-1-60473-701-1. Archived from the original on October 31, 2016.
68. ^ Organization WH (2011). Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. World Health Organization. hdl:10665/85839.
69. World Health Organization (2008). Worldwide prevalence of anaemia 1993–2005 (PDF). Geneva: World Health Organization. ISBN 978-92-4-159665-7. Archived (PDF) from the original on March 12, 2009. Retrieved March 25, 2009.
70. "Anemia". Radiologyinfo.org. Retrieved October 11, 2021.
71. "How Anemia Is Diagnosed and Treated". WebMD. Retrieved October 11, 2021.
72. "Anemia Types, Treatment, Symptoms, Signs, Causes & Iron Deficiency". eMedicineHealth. Retrieved October 11, 2021.
73. Caito S, Lopes AC, Paoliello MM, Aschner M (2017). "Toxicology of Lead and Its Damage to Mammalian Organs". Lead – Its Effects on Environment and Health. Metal Ions in Life Sciences. Vol. 17. pp. 501–534. doi:10.1515/9783110434330-016. ISBN 978-3-11-043433-0. PMID 28731309.
74. Recommendations to Prevent and Control Iron Deficiency in the United States Archived 2007-04-20 at the Wayback Machine MMWR 1998;47 (No. RR-3) p. 5
75. Centers for Disease Control Prevention (CDC) (October 11, 2002). "Iron Deficiency – United States, 1999–2000". MMWR. 51 (40): 897–899. PMID 12418542. Archived from the original on May 5, 2012. Retrieved April 21, 2012.
76. "Global Iron-Deficiency Anemia Therapy Market – Industry Trends and Forecast to 2027 -". Data Bridge Market Research. Retrieved August 2, 2023.
77. Halterman JS, Kaczorowski JM, Aligne CA, Auinger P, Szilagyi PG (June 2001). "Iron deficiency and cognitive achievement among school-aged children and adolescents in the United States". Pediatrics. 107 (6): 1381–1386. doi:10.1542/peds.107.6.1381. PMID 11389261. S2CID 33404386.
78. Grantham-McGregor S, Ani C (February 2001). "A review of studies on the effect of iron deficiency on cognitive development in children". The Journal of Nutrition. 131 (2S–2): 649S–666S, discussion 666S–668S. doi:10.1093/jn/131.2.649S. PMID 11160596.
79. "Iron Deficiency Anaemia: Assessment, Prevention, and Control: A guide for programme managers" (PDF). Archived from the original (PDF) on May 16, 2011. Retrieved August 24, 2010.
80. Mentzer WC (April 1973). "Differentiation of iron deficiency from thalassaemia trait". Lancet. 1 (7808): 882. doi:10.1016/s0140-6736(73)91446-3. PMID 4123424.
81. Long B, Koyfman A (August 2018). "Emergency Medicine Evaluation and Management of Anemia". Emergency Medicine Clinics of North America. 36 (3): 609–630. doi:10.1016/j.emc.2018.04.009. PMID 30037447.
82. eMedicine – "Vitamin B-12 Associated Neurological Diseases": Article by Niranjan N Singh, July 18, 2006. Archived 2007-03-15 at the Wayback Machine.
83. "Physiology or Medicine 1934 – Presentation Speech". Nobelprize.org. December 10, 1934. Archived from the original on August 28, 2010. Retrieved August 24, 2010.
84. ^ Harvey JW (2012). Veterinary hematology: a diagnostic guide and color atlas. St. Louis, MO: Elsevier/Saunders. p. 104. ISBN 978-1-4377-0173-9.
85. Hovda L, Brutlag A, Poppenga RH, Peterson K, eds. (2016). "Chapter 69: Onions and garlic". Blackwell's Five-Minute Veterinary Consult Clinical Companion: Small Animal Toxicology (2nd ed.). John Wiley & Sons. pp. 515–520. ISBN 978-1-119-03652-4.
86. Peek SF (2015). "Hemolytic Disorders". Robinson's Current Therapy in Equine Medicine. pp. 492–495. doi:10.1016/B978-1-4557-4555-5.00117-5. ISBN 978-1-4557-4555-5.
87. Wallerstein RO (April 1987). "Laboratory evaluation of anemia". The Western Journal of Medicine. 146 (4): 443–451. PMC 1307333. PMID 3577135.
88. "MedTerms Definition: Refractory Anemia". Medterms.com. April 27, 2011. Archived from the original on December 8, 2011. Retrieved October 31, 2011.
89. "Good Source for later". Atlasgeneticsoncology.org. Archived from the original on November 3, 2011. Retrieved October 31, 2011.
90. Mody RJ, Brown PI, Wechsler DS (February 2003). "Refractory iron deficiency anemia as the primary clinical manifestation of celiac disease". Journal of Pediatric Hematology/Oncology. 25 (2): 169–172. doi:10.1097/00043426-200302000-00018. PMID 12571473. S2CID 38832868.
91. Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B, et al. (January 2011). "What are RBC-transfusion-dependence and -independence?". Leukemia Research. 35 (1): 8–11. doi:10.1016/j.leukres.2010.07.015. PMC 8215731. PMID 20692036.
92. ^ Melchert M, List AF (2007). "Management of RBC-transfusion dependence". Hematology. American Society of Hematology. Education Program. 2007: 398–404. doi:10.1182/asheducation-2007.1.398. PMID 18024657.
93. Hillyer CD, Silberstein LE, Ness PM, Anderson KC, Roback JD (2006). Blood Banking and Transfusion Medicine: Basic Principles and Practice. Elsevier Health Sciences. p. 534. ISBN 9780702036255.
94. Mandel J, Taichman D (2006). Pulmonary Vascular Disease. Elsevier Health Sciences. p. 170. ISBN 978-1416022466.
95. Ferri FF (2015). BOPOD – Ferri's Clinical Advisor 2016. Elsevier Health Sciences. p. 1131.e2. ISBN 978-0323378222.
96. West CE (November 1996). "Strategies to control nutritional anemia". The American Journal of Clinical Nutrition. 64 (5): 789–790. doi:10.1093/ajcn/64.5.789. PMID 8901803.
97. Low MS, Speedy J, Styles CE, De-Regil LM, Pasricha SR (April 18, 2016). "Daily iron supplementation for improving anaemia, iron status and health in menstruating women". The Cochrane Database of Systematic Reviews. 2016 (4): CD009747. doi:10.1002/14651858.CD009747.pub2. PMC 10182438. PMID 27087396.
98. Sezer S, Ozdemir FN, Yakupoglu U, Arat Z, Turan M, Haberal M (April 2002). "Intravenous ascorbic acid administration for erythropoietin-hyporesponsive anemia in iron loaded hemodialysis patients". Artificial Organs. 26 (4): 366–370. doi:10.1046/j.1525-1594.2002.06888.x. PMID 11952508.
99. "Anaemia management in people with chronic kidney disease | Guidance and guidelines | NICE". February 9, 2011. Archived from the original on June 24, 2013. Retrieved August 9, 2013.
100. Ng O, Keeler BD, Mishra A, Simpson JA, Neal K, Al-Hassi HO, Brookes MJ, Acheson AG (December 7, 2019). "Iron therapy for preoperative anaemia". Cochrane Database of Systematic Reviews. 2019 (12): CD011588. doi:10.1002/14651858.CD011588.pub3. PMC 6899074. PMID 31811820.
101. Auerbach M, Ballard H (2010). "Clinical use of intravenous iron: administration, efficacy, and safety". Hematology. American Society of Hematology. Education Program. 2010: 338–347. doi:10.1182/asheducation-2010.1.338. PMID 21239816.
102. ^ Kansagara D, Dyer E, Englander H, Fu R, Freeman M, Kagen D (December 2013). "Treatment of anemia in patients with heart disease: a systematic review". Annals of Internal Medicine. 159 (11): 746–757. doi:10.7326/0003-4819-159-11-201312030-00007. PMID 24297191. S2CID 27062899.
103. Goddard AF, James MW, McIntyre AS, Scott BB (October 2011). "Guidelines for the management of iron deficiency anaemia". Gut. 60 (10). British Society of Gastroenterology: 1309–1316. doi:10.1136/gut.2010.228874. PMID 21561874.
104. Preston NJ, Hurlow A, Brine J, Bennett MI (February 15, 2012). "Blood transfusions for anaemia in patients with advanced cancer". Cochrane Database of Systematic Reviews. 2012 (2): CD009007. doi:10.1002/14651858.CD009007.pub2. PMC 7388847. PMID 22336857.
105. "Pernicious anemia: MedlinePlus Medical Encyclopedia". medlineplus.gov. Retrieved August 4, 2022.
106. Hankey GJ (2008). Clinical neurology. Joanna M. Wardlaw. London: Manson. ISBN 978-1-84076-518-2. OCLC 503441695.
107. ^ Langan RC, Goodbred AJ (September 15, 2017). "Vitamin B12 Deficiency: Recognition and Management". American Family Physician. 96 (6): 384–389. PMID 28925645.
108. ^ Aapro MS, Link H (2008). "September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents". The Oncologist. 13 Suppl 3 (Supplement 3): 33–36. doi:10.1634/theoncologist.13-S3-33. PMID 18458123.
109. American Society of Nephrology, "Five Things Physicians and Patients Should Question" (PDF), Choosing Wisely: an initiative of the ABIM Foundation, American Society of Nephrology, archived (PDF) from the original on April 16, 2012, retrieved August 17, 2012
110. Kaufner L, Heymann C (2020). "Erythropoietin plus iron versus control treatment including placebo or iron for preoperative anaemic adults undergoing non-cardiac surgery". Cochrane Database of Systematic Reviews. 2020 (8): CD012451. doi:10.1002/14651858.CD012451.pub2. PMC 8095002. PMID 32790892.
111. ^ Undersea and Hyperbaric Medical Society. "Exceptional Blood Loss – Anemia". Archived from the original on July 5, 2008. Retrieved May 19, 2008.
112. Hart GB, Lennon PA, Strauss MB (1987). "Hyperbaric oxygen in exceptional acute blood-loss anemia". J. Hyperbaric Med. 2 (4): 205–210. Archived from the original on January 16, 2009. Retrieved May 19, 2008.{{cite journal}}: CS1 maint: unfit URL (link)
113. Van Meter KW (2005). "A systematic review of the application of hyperbaric oxygen in the treatment of severe anemia: an evidence-based approach". Undersea & Hyperbaric Medicine. 32 (1): 61–83. PMID 15796315. Archived from the original on January 16, 2009.{{cite journal}}: CS1 maint: unfit URL (link)
114. ^ Kaufner L, von Heymann C, Henkelmann A, Pace NL, Weibel S, Kranke P, Meerpohl JJ, Gill R (August 13, 2020). "Erythropoietin plus iron versus control treatment including placebo or iron for preoperative anaemic adults undergoing non-cardiac surgery". Cochrane Database of Systematic Reviews. 2020 (8): CD012451. doi:10.1002/14651858.CD012451.pub2. PMC 8095002. PMID 32790892.
115. Kotzé A, Harris A, Baker C, Iqbal T, Lavies N, Richards T, Ryan K, Taylor C, Thomas D (November 2015). "British Committee for Standards in Haematology Guidelines on the Identification and Management of Pre-Operative Anaemia". British Journal of Haematology. 171 (3): 322–331. doi:10.1111/bjh.13623. PMID 26343392. S2CID 37709527.
116. Kassebaum NJ, GBD 2013 Anemia Collaborators (2016). "The Global Burden of Anemia". Hematology/Oncology Clinics of North America. 30 (2): 247–308. doi:10.1016/j.hoc.2015.11.002. PMID 27040955.
117. van Hensbroek MB, Jonker F, Bates I (September 2011). "Severe acquired anaemia in Africa: new concepts". British Journal of Haematology. 154 (6): 690–5. doi:10.1111/j.1365-2141.2011.08761.x. PMID 21707575. S2CID 205268648.
118. Abuga KM, Muriuki JM, Williams TN, Atkinson SH (September 22, 2020). "How Severe Anaemia Might Influence the Risk of Invasive Bacterial Infections in African Children". International Journal of Molecular Sciences. 21 (18): 6976. doi:10.3390/ijms21186976. PMC 7555399. PMID 32972031.
119. Tayles N (September 1996). "Anemia, genetic diseases, and malaria in prehistoric mainland Southeast Asia". American Journal of Physical Anthropology. 101 (1): 11–27. doi:10.1002/(SICI)1096-8644(199609)101:1<11::AID-AJPA2>3.0.CO;2-G. PMID 8876811.

External links

• WHO fact sheet on anaemia
• Anemia, U.S. National Library of Medicine

• Anemias
• Hematopathology
• Transfusion medicine